ulcerative colitis
Second trial opens door for Lilly’s mirikizumab in ulcerative colitis
Phil Taylor
Eli Lilly, inflammatory bowel disease, mirikizumab, ulcerative colitis
0 Comment
Etrasimod data suggests Pfizer’s $6.7bn gamble on Arena will pay off
Phil Taylor
Bristol-Myers Squibb, etrasimod, Immunology and inflammation, Pfizer, ulcerative colitis, Zeposia
0 Comment
Lilly unveils mirikizumab data in ulcerative colitis as it preps filings
Phil Taylor
Eli Lilly, inflammatory bowel disease, mirikizumab, ulcerative colitis
0 Comment
Flush with COVID cash, Pfizer tables $6.7bn bid for Arena
Phil Taylor
Arena Pharmaceuticals, Bristol-Myers Squibb, etrasimod, Immunology and inflammation, M&A, Pfizer, ulcerative colitis, Zeposia
0 Comment
Failed IBD trial dents confidence in BMS’ deucravacitinib
Phil Taylor
Amgen, Bristol-Myers Squibb, deucravacitinib, inflammatory bowel disease, Otezla, ulcerative colitis
0 Comment
Trials leave Galapagos’ SIK programme looking under the weather
Phil Taylor
Galapagos, Gilead Sciences, psoriasis, Rheumatoid arthritis, SIK inhibitor, ulcerative colitis
0 Comment
Crowded psoriasis market cuts Lilly’s mirikizumab ambitions
Phil Taylor
Crohn's disease, dermatology, Eli Lilly, gastrointestinal, Immunology and inflammation, mirikizumab, psoriasis, ulcerative colitis
0 Comment
Lilly’s mirikuzumab hits target in phase 3 ulcerative colitis trial
Richard Staines
Eli Lilly, inflammatory diseases, mirikizumab, ulcerative colitis
0 Comment